Half-life & storage reference
One table for quick lookups: typical research dose (from our research notes) and reported elimination half-life. We only print a half-life when there's a documented basis — 26 of 79 compounds here have one; the rest are honestly marked "not established" rather than guessed.
Educational reference only — not medical advice. Half-life varies with route, dose and formulation; values are approximate central estimates from the tagged source type.
Storage in 20 seconds
- Lyophilized (powder) vials: stable through normal shipping; store sealed, dark and dry. Refrigerate (2–8 °C) for weeks-to-months, freeze (−20 °C) for long-term.
- After reconstitution with bacteriostatic water: refrigerate at 2–8 °C, swirl gently (never shake), and avoid freeze–thaw cycles. Community practice is to use a reconstituted vial within a few weeks.
- Approved drug products (e.g. GLP-1 pens): follow the label, not general rules.
Stability is compound-specific — when a vendor or label gives explicit guidance, it wins. Use the calculator to work out concentrations and syringe draws.
| Peptide | Primary use | Typical research dose | Reported half-life | Basis |
|---|---|---|---|---|
| 5-Amino-1MQ | Weight Loss | 50-150 mg taken orally once daily, sometimes split into two doses with food | Not established | — |
| A4 Amyloid Beta | Memory | 1.7 g | Not established | — |
| ACE-031 | Muscle | 0.02-3 mg | Not established | — |
| Adiponectin | Weight Loss | 220 mg | Not established | — |
| Adipotide | Weight Loss | 0.43 mg/kg (primate) | Not established | — |
| AHK (Tripeptide-3) | Recovery | Topical Concentr… | Not established | — |
| AHK-Cu | Recovery | Research Concent… | Not established | — |
| AOD-9604 | Weight Loss | 0.25 mg | Not established | — |
| ARA-290 | Recovery | 4 mg | Not established | — |
| Argireline | General | Topical Concentr… | Not established | — |
| B7-33 | Longevity | 1-5 mg | Not established | — |
| BPC-157 | Recovery | 200-500 mcg | No human PK published | — |
| Bronchogen | Immunity | Typical Protocol | Not established | — |
| Cagrilintide | Weight Loss | 0.3 mg | ≈7–8 days | PK study |
| Cardiogen | Recovery | 1-5 mg | Not established | — |
| Cartalax | Recovery | 0.1 mg | Not established | — |
| Cerebrolysin | Memory | Clinical Range | Not established | — |
| Chitosan | Weight Loss | 160 mg | Not established | — |
| Chonluten | Recovery | 100-200 mcg | Not established | — |
| CJC-1295 | Muscle | 1-2 mg | ≈30 min (without DAC) | Literature |
| CJC-1295 / Ipamorelin Blend | Muscle | 100-200 mcg of each peptide together (0.2-0.4 mg total blend), once or twice daily on an empty stomach | Not established | — |
| CJC-1295 + DAC | Muscle | 1-2 mg | ≈6–8 days (with DAC) | PK study |
| Collagen Peptides | Recovery | 10-20 g | Not established | — |
| Cortagen | Recovery | 5 mg | Not established | — |
| Decapeptide-12 | Longevity | Standard Concent… | Not established | — |
| Demoxytocin | Mood | 10 IU | Not established | — |
| Dihexa | Memory | 5-20 mg | Not established | — |
| DSIP (Delta Sleep-Inducing Peptide) | Sleep | 100-300 mcg | ≈7–8 min | PK study |
| Epitalon | Longevity | 10 mg | Not established | — |
| Follistatin 344 | Muscle | 100 mcg | Not established | — |
| FOXO4-DRI | Longevity | 2.5 mg | Not established | — |
| GDF-11 | Longevity | 4.5 mg | Not established | — |
| GHK-Cu | Recovery | 1-2 mg | <1 h (plasma) | Literature |
| Ghrelin | Energy | Frequency | ≈10–30 min | PK study |
| GHRP-2 | Muscle | 100-300 mcg | ≈30 min | PK study |
| GHRP-6 | Muscle | 100-300 mcg | ≈20–30 min | Literature |
| GLOW | Recovery | 10 units (0.1 mL / 3.5 mg total blend) once daily; common range ~5-20 units/day | Not established | — |
| GLP-1 | Weight Loss | 0.25 mg | ≈1–2 min (native hormone) | PK study |
| Glutathione | Recovery | 200-600 mg IM or subcutaneously, 1-3 times per week; IV clinic doses are larger. | Not established | — |
| Gonadorelin | Libido | 0.25 mg | ≈2–10 min | FDA label |
| HCG | Libido | 250 IU | ≈24–36 h | PK study |
| Hexarelin | Muscle | 100-200 mcg | ≈55–70 min | PK study |
| HGH (Somatropin) | Muscle | 1-2 IU/day for anti-aging or GH optimization; 2-4 IU/day for body composition. Clinical deficiency dosing is much lower, ~0.2-0.4 mg/day, physician-titrated to IGF-1. | Not established | — |
| HMG | Libido | 75-150 IU | Not established | — |
| Human Relaxin-2 | Longevity | 30 μg | Not established | — |
| Humanin | Longevity | HNG Analog | Not established | — |
| Ibutamoren (MK-677) | Sleep | 10-25 mg | ≈24 h | PK study |
| IGF-1 LR3 | Muscle | 20-50 mcg daily | Not established | — |
| Ipamorelin | Muscle | 100-300 mcg | ≈2 h | PK study |
| Kisspeptin | Libido | Research Protocols | ≈4 min (kisspeptin-10) | PK study |
| KLOW | Recovery | 10 units (0.1 mL / 4.0 mg total blend) once daily; common range ~5-20 units/day | Not established | — |
| KPV | Immunity | 200-500 mcg daily | Not established | — |
| L-Carnitine | Weight Loss | 200-500 mg per injection | Not established | — |
| LL-37 | Immunity | 100-500 mcg | Not established | — |
| Melanotan 1 | Longevity | 0.5-1 mg | ≈30 min | FDA label |
| Melanotan 2 | Libido | 0.25 mg | ≈30–60 min | Literature |
| Modified GRF 1-29 | Muscle | 50-100 mcg | ≈30 min | Literature |
| MOTS-c | Energy | 5-10 mg per week (divided) | Not established | — |
| NAD+ | Longevity | 50-100 mg subcutaneously, often daily or a few times weekly; clinic IV 250-1000 mg per slow infusion. | Not established | — |
| PE-22-28 | Mood | No human dose ha… | Not established | — |
| Pinealon | Sleep | 100 mcg | Not established | — |
| Pramlintide | Weight Loss | 15 mcg | ≈48 min | FDA label |
| Prostatilen | Recovery | 5-10 mg | Not established | — |
| PT-141 | Libido | 1.75 mg | ≈2–4 h | FDA label |
| Retinalamin | Recovery | 5 mg | Not established | — |
| Selank | Anxiety | 150-900 mcg | Minutes (rapid enzymatic breakdown) | Literature |
| Semax | Memory | 200-600 mcg | Minutes (rapid enzymatic breakdown) | Literature |
| Sermorelin | Muscle | 200-500 mcg | ≈10–20 min | FDA label |
| SLU-PP-332 | Energy | No established human dose; anecdotal SC protocols use roughly 250 mcg to 1 mg per day | Not established | — |
| SS-31 | Energy | 5 mg | ≈2–4 h (elamipretide) | PK study |
| TB-500 | Recovery | 4-10 mg | ≈1–2 h (thymosin β4) | Literature |
| Tesamorelin | Weight Loss | 2 mg once daily subcutaneously (label standard; some protocols start at 1 mg) | Not established | — |
| Thymalin | Immunity | 10 mg | Not established | — |
| Thymosin Alpha-1 | Immunity | 1.6 mg twice weekly (subQ) | Not established | — |
| Tirzepatide | Weight Loss | 2.5-15 mg once weekly | Not established | — |
| Vilon | Immunity | 1 mg | Not established | — |
| VIP Peptide | Pain | Experimental Dos… | ≈1–2 min | PK study |
| Vitamin B-12 (Methylcobalamin) | Energy | 1000 mcg (1 mg) per injection | Not established | — |
| Wolverine Stack | Recovery | 200-500 mcg | Not established | — |
Basis tags — FDA label: prescribing information of an approved drug form · PK study: published human pharmacokinetics · Literature: reported in published research with weaker or animal-derived data. Click any peptide for its protocol notes and primary studies.